Cargando…
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
The optimal treatment strategy for Parkinson's disease has been debated for decades. The introduction of levodopa (LD) treatment is frequently delayed because of theoretical concerns about its toxicity or the risk of drug-induced motor complications. These concerns have resulted in “LD phobia”...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876591/ https://www.ncbi.nlm.nih.gov/pubmed/26644151 http://dx.doi.org/10.2174/1570159X14666151208114634 |
_version_ | 1782433261625016320 |
---|---|
author | Zhang, Jinglin Tan, Louis Chew-Seng |
author_facet | Zhang, Jinglin Tan, Louis Chew-Seng |
author_sort | Zhang, Jinglin |
collection | PubMed |
description | The optimal treatment strategy for Parkinson's disease has been debated for decades. The introduction of levodopa (LD) treatment is frequently delayed because of theoretical concerns about its toxicity or the risk of drug-induced motor complications. These concerns have resulted in “LD phobia” with clinicians selecting dopamine agonist (DA) over LD as initial therapy. More recently, a shift in the treatment approach towards initial LD use appears to be occurring. It is therefore necessary to review current evidence for the use of LD and DA. This review discusses the medical management of Parkinson's disease with regards to the use of LD versus DA. Pendulum swings in treatment strategies between LD-first and DA-first therapies should be avoided. A balanced perspective is needed as there is a place for both drugs in the management of PD. |
format | Online Article Text |
id | pubmed-4876591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-48765912016-11-01 Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist Zhang, Jinglin Tan, Louis Chew-Seng Curr Neuropharmacol Article The optimal treatment strategy for Parkinson's disease has been debated for decades. The introduction of levodopa (LD) treatment is frequently delayed because of theoretical concerns about its toxicity or the risk of drug-induced motor complications. These concerns have resulted in “LD phobia” with clinicians selecting dopamine agonist (DA) over LD as initial therapy. More recently, a shift in the treatment approach towards initial LD use appears to be occurring. It is therefore necessary to review current evidence for the use of LD and DA. This review discusses the medical management of Parkinson's disease with regards to the use of LD versus DA. Pendulum swings in treatment strategies between LD-first and DA-first therapies should be avoided. A balanced perspective is needed as there is a place for both drugs in the management of PD. Bentham Science Publishers 2016-05 2016-05 /pmc/articles/PMC4876591/ /pubmed/26644151 http://dx.doi.org/10.2174/1570159X14666151208114634 Text en © 2016 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Zhang, Jinglin Tan, Louis Chew-Seng Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist |
title | Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist |
title_full | Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist |
title_fullStr | Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist |
title_full_unstemmed | Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist |
title_short | Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist |
title_sort | revisiting the medical management of parkinson's disease: levodopa versus dopamine agonist |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876591/ https://www.ncbi.nlm.nih.gov/pubmed/26644151 http://dx.doi.org/10.2174/1570159X14666151208114634 |
work_keys_str_mv | AT zhangjinglin revisitingthemedicalmanagementofparkinsonsdiseaselevodopaversusdopamineagonist AT tanlouischewseng revisitingthemedicalmanagementofparkinsonsdiseaselevodopaversusdopamineagonist |